Navigation Links
GenVec Announces Research on Improved Vaccine Vectors
Date:4/6/2012

GAITHERSBURG, Md., April 6, 2012 /PRNewswire/ -- GenVec, Inc. (NASDAQ:   GNVC) announced publication of research on GenVec's new vaccine vectors. These vectors circumvent neutralizing antibodies in order to generate the desired immunologic response. The paper has been published online in PloS ONE, and can be accessed at http://dx.plos.org/10.1371/journal.pone.0033920. The article titled "Modification of Ad5 Hexon Hypervariable Regions Circumvents Pre-existing Ad5 Neutralizing Antibodies and Induces Protective Immune Responses" is an example of GenVec's proprietary vaccine technology.

"This paper describes one of several new tools we are using to generate better vaccines," noted Douglas E. Brough, Ph.D., GenVec's Vice President of Research.  "This approach alters key elements of the vector so that a good vaccine response is generated even if an individual was previously exposed to an adenovirus.  This technology expands our genetic vaccine toolbox used to create superior vaccines."

About GenVec

GenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD). Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding funding, grants, collaborations, revenues, cash burn rates, the development of products and the success of the collaboration with Novartis, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to research and development activities; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of collaborators and third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. These forward looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.

 

Retail Investor and Media Contact:

GenVec, Inc.

Douglas J. Swirsky

(240) 632-5510

dswirsky@genvec.com

Institutional Investor Contact:

S.A. Noonan Communications

Susan A. Noonan

(212) 966-3650

susan@sanoonan.com


'/>"/>
SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
2. GenVec Expands Contract Supporting Malaria Vaccine Program
3. GenVec Reports Second Quarter 2009 Financial Results
4. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
5. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
6. GenVec Announces Third Quarter 2009 Results Conference Call
7. GenVec Reports Third Quarter 2009 Financial Results
8. Merriman Curhan Ford Acted as Placement Agent in GenVecs $28 Million Registered Offering
9. GenVec to Present at the 13th Annual BIO CEO & Investor Conference
10. GenVec To Host Fourth Quarter and Year-End 2010 Earnings Call and Webcast
11. GenVec, Inc. Announces Effectiveness of Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... Salford-based ... for the food and pharmaceutical processing and packaging industries, was runner-up for the ... that has done the most or taken the most innovative steps to improve ...
(Date:2/20/2017)... , ... February 20, 2017 ... ... US Joint Commission Accredited venture-backed teleradiology and telemedicine company announces at HIMSS ... USARAD services are planned to be offered via a global cloud-based sharing ...
(Date:2/20/2017)... San Francisco, CA (PRWEB) , ... February 20, ... ... to reduce infections in patients with catheters associated with peritoneal dialysis, announced today ... (UV) light-based peritoneal dialysis catheter connection system in Peritoneal Dialysis International (PDI), ...
(Date:2/20/2017)... 20, 2017  At the 2017 Health Information ... Orlando , IBM (NYSE: IBM ) ... IBM Chairman, President and CEO Ginni Rometty ... today from 8:30-10 am ET, broadcast live on ... Her remarks examine the advent of the Cognitive ...
Breaking Biology Technology:
(Date:2/1/2017)... BOSTON, Massachusetts , February 1, 2017 ... and events on emerging technology, announces the availability of a new ... Continue Reading ... ... systems in industrial and collaborative robots. Source: IDTechEx Report "Sensors for ...
(Date:1/30/2017)... , Jan. 30, 2017   Invitae Corporation ... fastest growing genetic information companies, today announced that it ... results and provide 2017 guidance on Monday, February 13, ... call that day at 4:45 p.m. Eastern / 1:45 ... management team will briefly review financial results, guidance, and ...
(Date:1/26/2017)... 2017  Acuity Market Intelligence today released the ... Identity".  Acuity characterizes 2017 as a "breakout" year ... reflects a new understanding of the potential benefits ... digital identity are often perceived as threats to ... Principal of Acuity Market intelligence. "However, taken together ...
Breaking Biology News(10 mins):